Drug Information

Drug General Information
Drug ID
D0X3FX
Former ID
DAP000097
Drug Name
Naloxone
Synonyms
Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one
Drug Type
Small molecular drug
Indication Narcotic depression [ICD9: 304.9, 311; ICD10:F19.20, F32] Approved [536655], [539031]
Therapeutic Class
Antinarcotic Agents
Company
Bristol Meyers Squibb
Structure
Download
2D MOL

3D MOL
Formula
C19H21NO4
InChI
InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19+/m1/s1
InChIKey
UZHSEJADLWPNLE-FCLVOEFKSA-N
CAS Number
CAS 465-65-6
PubChem Compound ID
71774987
PubChem Substance ID
135330618, 135650685
ChEBI ID
ChEBI:7459
SuperDrug ATC ID
V03AB15
SuperDrug CAS ID
cas=000465656
Target and Pathway
Target(s) Mu-type opioid receptor Target Info Antagonist [536514], [537190]
KEGG Pathway Neuroactive ligand-receptor interaction
Estrogen signaling pathway
Morphine addiction
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Enkephalin release
Pathway Interaction Database IL4-mediated signaling events
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways TCR Signaling Pathway
GPCRs, Class A Rhodopsin-like
Peptide GPCRs
Opioid Signalling
GPCR ligand binding
GPCR downstream signaling
References
Ref 536655Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. J Manag Care Pharm. 2008 Mar;14(2):186-94.
Ref 539031(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1668).
Ref 536514Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007 Nov;2(11):1552-70.
Ref 537190OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.